| Kimberly Marie Herrig, | |
|
530 E 2nd St, Duluth, MN 55805-1913 | |
| (218) 786-5360 | |
| Not Available |
| Full Name | Kimberly Marie Herrig |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 530 E 2nd St, Duluth, Minnesota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1912926361 | NPI | - | NPPES |
| 6404584 | Other | MEDICA | |
| 40872900 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | 102905 (Minnesota) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Kimberly Marie Herrig, 530 E 2nd St, Duluth, MN 55805-1913 Ph: (218) 786-5360 | Kimberly Marie Herrig, 530 E 2nd St, Duluth, MN 55805-1913 Ph: (218) 786-5360 |
News Archive
Juvenile idiopathic arthritis (JIA) is a the most common form of arthritis in children and affects approximately 50,000 individuals in the United States alone. Previous research suggested that autoimmune responses cause JIA, but the specific antigens that are responsible for driving autoimmunity have not been identified.
The U.S. Food and Drug Administration today announced the availability of the first draft guidance for industry on Risk Evaluation and Mitigation Strategies or REMS, which are required for certain drugs or biologics.
European research lays the foundation for the development of new and ambitious research projects with xenografts derived from patients, preclinical models with great potential to advance research and treatment in cancer.
New research based on post-hospital arrival data from U.S. trauma centers finds that even after adjusting for differences in injury severity, gun use, and other likely causes of race difference in death from assault, African-Americans have a significantly higher overall post-scene of injury mortality rate than whites.
DURECT Corporation today announced the successful completion of a Phase 1 clinical trial with an injectable formulation of DUR-928 intended for acute use indications. DUR-928 is an endogenous, small-molecule, new chemical entity (NCE), which may have broad applicability in metabolic diseases such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), and in acute organ injuries such as acute kidney injury (AKI).
› Verified 1 days ago
Jamie R Smith, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 502 E 2nd St, Duluth, MN 55805 Phone: 218-727-8762 | |
Mrs. Mindy Joy Delacey, O.T. Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 530 E 2nd St, Essentia Health Polinsky Medical Rehabilitation Center, Duluth, MN 55805 Phone: 218-786-5360 | |
Jenna Maki, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 407 E 3rd St, Duluth, MN 55805 Phone: 218-786-4000 | |
Charlene Schneider Dillon, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 530 E 2nd St, Duluth, MN 55805 Phone: 218-786-5360 | |
Melissa Grace Julian, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 407 E 3rd St, Essentia Health Duluth Clinic, Duluth, MN 55805 Phone: 218-786-4000 | |
Joy Zamzow, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 66 E Saint Marie St, Duluth, MN 55803 Phone: 218-481-7603 Fax: 218-481-7601 | |
Mr. Sean P Witte, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1506 N Central Ave, Duluth, MN 55807 Phone: 218-343-1904 |